CLXT News and Press, Calyxt Inc. From 05/05/22

Calyxt press release (NASDAQ:CLXT): Q1 Non-GAAP EPS of -$0.14 beats by $0.03. Revenue of $0.03M (-99.3% Y/Y) misses by $0.35M. Shares +4%. For further details see: Calyxt Non-GAAP EPS of -$0.14 beats by $0.03, revenue of $0.03M misses by $0.35M

Calyxt Reports First Quarter 2022 Financial Results PR Newswire Achieved technical BioFactory™ and AIML milestones to support customer demand-driven molecule development at scale Progressed relationships with an expanding network of potential new custome...

Calyxt (NASDAQ:CLXT) is scheduled to announce Q1 earnings results on Thursday, May 5th, after market close. The consensus EPS Estimate is -$0.17 (+29.2% Y/Y) and the consensus Revenue Estimate is $0.42M (-90.5% Y/Y). Over the last 1 year, CLXT has beaten EPS estimates 0% of the time and has b...

Calyxt Announces Strategic Hires in Business Development and Manufacturing PR Newswire Continued investment in key hires to strategically position Company for future growth and scale ROSEVILLE, Minn. , April 26, 2022 /PRNewswire/ -- Calyxt, In...

Calyxt to Host First Quarter 2022 Financial Results Conference Call and Webcast on Thursday, May 5, 2022, at 4:30 p.m. Eastern Time PR Newswire ROSEVILLE, Minn. , April 21, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic ...

Shares of Calyxt Inc. (NASDAQ:CLXT) traded today at $31.72, eclipsing its 52-week high. This new high was reached on above average trading volume as 15.2 million shares traded hands, while the average 30-day volume is approximately 538,000 shares. Calyxt Inc. share prices have moved betw...

Calyxt is now on to its third business plan, pivoting from gene-edited seed traits to synthetic biology. The company is looking to produce molecules of interest to pharmaceutical, nutraceutical, and cosmeceutical companies through sustainable plant-based technology. The underlying...

Calyxt to Participate in Fireside Chat at the 34th Annual Roth Conference PR Newswire ROSEVILLE, Minn. , March 8, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that management will participate i...

The following slide deck was published by Calyxt, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Calyxt, Inc. 2022 Q4 - Results - Earnings Call Presentation

Calyxt, Inc. (CLXT) Q4 2021 Earnings Conference Call March 3, 2022, 4:30 PM ET Company Participants Bill Koschak - Chief Financial Officer Michael Carr - President and CEO Conference Call Participants Laurence Alexander - Jefferies Bobby Burleson - Canaccord Brian Wright - ROTH Capital Partne...